Advaxis, Inc. , a clinical-stage biotechnology company developing cancer immunotherapies, announced today that its Lm -LLO immunotherapy technology is featured in an article in the December 2014 issue of Nature Biotechnology . Entitled " Listeria vaccines join the checkpoint frenzy," the article explores the potential of the Listeria bacterium as a vector to enhance an anti-tumor response given its ability to induce powerful innate and adaptive immune responses.